A passive equilibration method which relies on addition of candidate drugs to pre-formed liposomes is described as an alternative method for preparing liposome encapsulated drugs. The method is simple, rapid and applicable to liposomes prepared with high (45 mol%) or low (b20 mol%) levels of cholesterol. Passive equilibration is performed in 4-steps: (i) formation of liposomes, (ii) addition of the candidate drug to the liposomes in combination with a permeability enhancing agent, (iii) incubation at a temperature that facilitates diffusion of the added compound across the lipid bilayer, and (iv) quenching the enhanced membrane permeability by reduction in temperature and/or removal of the permeabilization enhancer. The method is fully exemplified here using ethanol as the permeabilization enhancer and carboplatin (CBDCA) as the drug candidate. It is demonstrated that ethanol can be added to liposomes prepared with 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and Cholesterol (Chol) (55:45 mol ratio) in amounts up to 30% (v/v) with no change in liposome size, even when incubated at temperatures N 60°C. Super-saturated solutions of CBDCA (40 mg/mL) can be prepared at 70°C and these are stable in the presence of ethanol even when the temperature is reduced to b30°C. maximum CBDCA encapsulation is achieved within 1 h after the CBDCA solution is added to pre-formed DSPC/Chol liposomes in the presence of 30% (v/v) ethanol at 60°C. When the pre-formed liposomes are mixed with ethanol (30% v/v) at or below 40°C, the encapsulation efficiency is reduced by an order of magnitude. The method was also applied to liposomes prepared from other compositions include a cholesterol free formulations (containing 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (DSPE-PEG 2000 )) and a low Chol (b 20 mol%) formulations prepared with the distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol) DSPG)). The cytotoxic activity of CBDCA was unaffected when prepared in this manner and two of the resultant formulations exhibited good stability in vitro and in vivo. The cytotoxic activity of CBDCA was unaffected when prepared in this manner and the resultant formulations exhibited good stability in vitro and in vivo. Pharmacokinetics studies in CD-1 mice indicated that the resulting formulations increased the circulation half life of the associated CBDCA significantly (AUC 0-24 h of CBDCA = 0.016 μg·hr/mL; AUC 0-24h of the DSPC/Chol CBDCA formulation = 1014.0 μg·hr/mL and AUC 0-24h of the DSPC/DSPG/Chol CBDCA formulation = 583.96 μg·hr/mL). Preliminary efficacy studies in Rag-2M mice with established subcutaneous H1975 and U-251 tumors suggest that the therapeutic activity of CBDCA is improved when administered in liposomal formulations. The encapsulation method described here has not been disclosed previously and will have broad applications to drugs that would normally be encapsulated during liposome manufacturing.
A passive equilibration method which relies on addition of candidate drugs to pre-formed liposomes is described as an alternative method for preparing liposome encapsulated drugs. The method is simple, rapid and applicable to liposomes prepared with high (45 mol%) or low (b20 mol%) levels of cholesterol. Passive equilibration is performed in 4-steps: (i) formation of liposomes, (ii) addition of the candidate drug to the liposomes in combination with a permeability enhancing agent, (iii) incubation at a temperature that facilitates diffusion of the added compound across the lipid bilayer, and (iv) quenching the enhanced membrane permeability by reduction in temperature and/or removal of the permeabilization enhancer. The method is fully exemplified here using ethanol as the permeabilization enhancer and carboplatin (CBDCA) as the drug candidate. It is demonstrated that ethanol can be added to liposomes prepared with 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and Cholesterol (Chol) (55:45 mol ratio) in amounts up to 30% (v/v) with no change in liposome size, even when incubated at temperatures N 60°C. Super-saturated solutions of CBDCA (40 mg/mL) can be prepared at 70°C and these are stable in the presence of ethanol even when the temperature is reduced to b30°C. maximum CBDCA encapsulation is achieved within 1 h after the CBDCA solution is added to pre-formed DSPC/Chol liposomes in the presence of 30% (v/v) ethanol at 60°C. When the pre-formed liposomes are mixed with ethanol (30% v/v) at or below 40°C, the encapsulation efficiency is reduced by an order of magnitude. The method was also applied to liposomes prepared from other compositions include a cholesterol free formulations (containing 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (DSPE-PEG 2000 )) and a low Chol (b 20 mol%) formulations prepared with the distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol) DSPG)). The cytotoxic activity of CBDCA was unaffected when prepared in this manner and two of the resultant formulations exhibited good stability in vitro and in vivo. The cytotoxic activity of CBDCA was unaffected when prepared in this manner and the resultant formulations exhibited good stability in vitro and in vivo. Pharmacokinetics studies in CD-1 mice indicated that the resulting formulations increased the circulation half life of the associated CBDCA significantly (AUC 0-24 h of CBDCA = 0.016 μg·hr/mL; AUC 0-24h of the DSPC/Chol CBDCA formulation =key to the successful development and FDA approval of products like MyoCet® [1, 2] and Doxil® [3] (liposomal doxorubicin formulations), Marqibo® [4, 5] (a liposomal vincristine formulation) and others [6] . The manufacturing successes of these formulations were achieved, in part, through the development of efficient drug loading methods (N98% efficient) that facilitated the formation of products exhibiting high drug-to-lipid ratios and resulted in minimal unencapsulated drug loss [7] . Perhaps most importantly, the loading process (i.e. the step required to put the drug inside the liposome) was separated from the liposome manufacturing processes. Simple and scalable methods for manufacturing liposomes are in place based on the well-established extrusion methodology [8, 9] or emerging new methods relying on microfluidics [10] . These methods require the use of large mixing containers, low pressure pumps and/or some amount of continuous processing. When a cytotoxic drug is incorporated into these methods, it carries some risks to those manufacturing the product. When using remote loading, selected drugs with appropriate chemical attributes can be added to pre-formed liposomes. The added drug diffuses across the liposomal membrane, where a change in chemical properties results in the drug being better retained. Using pH gradient loading methods as an example, drugs exhibiting protonizable amine functions (e.g. doxorubicin, vincristine) can be added to pre-formed liposomes prepared with an internal pH that is acidic and an external pH that is neutral [11] [12] [13] . Provided that the pKa of the drug is close to the external pH, a significant portion of the drug exists in the neutral form which is membrane permeable. Once inside the liposome, however, the drug becomes protonated and charged. The charged form of the drug is not membrane permeable and is trapped [14] [15] [16] [17] . While versatile and efficient, this "remote loading" method is only applicable to drugs that have protonizable amine functions [12, 13] .
For drugs that cannot be loaded remotely, the alternative has been passive encapsulation where the compound of interest is added to dried lipid films or lipids solubilized in compatible solvents such as ethanol. The drug solution is processed with the lipids to prepare liposomes which, as indicated above, carry inherent risks. Further, the trapping efficiency of these methods can be very poor and is limited by the aqueous trapped volume of the liposome, the liposome size and the liposomal lipid concentration. Therefore, the loading efficiencies are low assuming the selected compound does not interact with the lipids used to prepare the liposome [18] . Additionally, because of issues related to non-equilibrium solute distribution, when using methods involving hydration of dried lipids, the concentration of solute in the aqueous space inside liposomes can be substantially lower than the concentration in the external solution [19, 20] . Since there is substantial waste of often expensive drugs, this method can be uneconomical [21] .
The studies reported here describe a process referred to as passive equilibration. The purpose of this system is to examine if drugs could be efficiently loaded into liposomes using simple equilibration approaches. This method relies on adding candidate drugs of interest to the outside of pre-formed liposomes in the presence of a permeability enhancer added in amounts that do not impact liposome structure (size) but do increase liposomal lipid bilayer permeability in a temperature-dependent manner. This allows for a safer, more economical, alternative method of drug loading which creates liposomal products with higher trapping effiencies. The method should be suitable for selected class 3 solvents deemed by the FDA to be less toxic and negative in genotoxicity studies [22] and is exemplified here using ethanol. It should be noted that others have reported on the use of ethanol for liposome manufacturing [23, 24] and ethanol-injection methods have been applied in large-scale production [25] as well as in novel microfluidic approaches [10] . In these examples, ethanol is added during the manufacturing process rather than after the preparation of liposomes. Further, we have previously reported that low amounts of ethanol can be added to cholesterol-free liposomes exhibiting a transmembrane pH gradient in order to enhance the rate of remote loading for drugs that have protonizable amine functions [26] . This previous study suggested that ethanol could be used to selectively enhance liposomal lipid bilayer permeability as the amount of added ethanol did not impact the transmembrane pH gradient but did affect the ability of the added compound to cross the lipid bilayer in response to the gradient.
The method described here was developed using carboplatin (CBDCA), a drug that exhibits limited aqueous solubility (~10 mg/mL) at room temperature [27] and has been prepared previously as a liposomal formulation using passive encapsulation methods [28] . The Log P of CBDCA is −0.46, suggesting very low permeability across lipid membranes [29] . The solubility of CBDCA can be increased by heating at 70°C to N40 mg/mL, however when incubated at room temperature the drug will precipitate from solution to achieve a solution concentration of~10 mg/mL within 1.5 h (unpublished observation). This can be accelerated by cooling the sample in an ice bath. We examined liposomes prepared from DSPC/Chol (55:45 mol ratio) to assess ethanol's influence on a stable formulation commonly used in the field. DSPC/ DSPG/Chol (70:20:10 mol ratio) liposomes were also studied to assess the effect of Chol content on ethanol-induced destabilization of the liposomes. We demonstrate that for DSPC/Chol (55:45 mol ratio) and DSPC/ DSPG/Chol (70:20:10 mol ratio) liposomes, ethanol can be added without affecting liposome size, even when incubated at 70°C. This effect has not been noted before and was exploited to allow for drug loading in liposomes, wherein the increase in lipid membrane permeability induced by temperature and ethanol can be rapidly decreased by simply decreasing temperature and/or removing ethanol. The compositions selected for these studies where designed to establish proof-of-principle. It is important to emphasize that the method could be applied to other lipid compositions, however the loading temperature and the type and concentration of the permeability enhancer used will need to be empirically determined. In the presence of ethanol, CBDCA was able to equilibrate across the DSPC/Chol lipid bilayer when incubated at ≥ 70°C, but not at temperatures ≤ 40°C. The trapping efficiency of CBDCA was 2-fold greater when compared to passive encapsulation methods where CBDCA solutions were used to hydrate DSPC/Chol mixtures prior to manufacturing. 
Materials and methods

Materials
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), Cholesterol (Chol), 1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DSPG) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [
Tissue culture
In vitro studies were completed using U-251 MG glioblastoma multiforme cells and in vivo studies were performed with U-251 MG and H1975 non-small cell lung cancer cells. H1975 cells were maintained at 37°C and 5% CO 2 in RPMI 1640 (Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco) and 2 mM L-glutamine (Gibco) while U-251 MG cells were cultured with DMEM supplemented with 10% FBS and 2 mM L-glutamine. Both U-251 MG glioblastoma cells (formerly known as U-373 MG) and H1975 cells were originally obtained from American Type Culture Collection (Manassas, VA). Our lab has recently purchased the U-251 MG from Sigma-Aldrich (product number 09063001). A microsatellite analysis was performed in order to compare these cells and the results indicate that the original cell line was derived from the Sigma-Aldrich sourced cells; however, the original line acquired deletions encompassing 21q21. 1 
Liposome preparation
Liposomes prepared from DSPC/Chol were used for these studies to assess ethanol's influence on what is commonly considered a stable and robust liposome formulation. Liposomes prepared from DSPC/ DSPG/Chol were used to assess the influence of Chol on ethanol-induced destabilization of the liposomes. As noted in previous studies [30] [31] [32] [33] , liposomes cannot be made from DSPC alone (without Chol) as they tend to aggregate after extrusion. To avoid this, two approaches have been reported in the literature. The first considers the use of PEG-modified lipids [31, 32, 34] and the second considers the use of charged lipids and more specifically phosphatidylglycerol [32, 35] . For these studies, we chose to use DSPG or DSPE-PEG 2000 as the component to stabilize the low cholesterol liposomes. It should be noted that the Tc of DSPC and DSPG are equal.
Liposomes were prepared from DSPC/Chol (55:45 mol ratio), DSPC/ DSPG/Chol (70:20:10 mol ratio), DSPC/Chol/DSPE-PEG 2000 (65:30:5 mol ratio) and DSPC/DSPE-PEG 2000 (95:5 mol ratio). The extrusion method for liposome preparation has been well-documented by others [8] . Briefly, lipids (stored at − 80°C) were desiccated for 2 h, weighed and dissolved in chloroform at the ratios indicated. A non-exchangeable and non-metabolizable lipid marker, 3 H-CHE, was incorporated into the chloroform mixture. The chloroform was removed using nitrogen gas and the thin film generated was further dried under high vacuum for 3 h. The generated lipid film was then rehydrated at 65°C in Sucrose Hepes (SH, 300 mM Sucrose, 20 mM HEPES) buffer at pH 7.4. Following hydration, the large multi-lamellar vesicles underwent 5 freeze (in liquid nitrogen) and thaw (65°C water bath) cycles [19] . These were then placed in an LIPEX™ Extruder (Northern Lipids Inc., Burnaby, British Columbia) and extruded through two stacked (100 nm) polycarbonate filters at least 10 times. The average size of the resulting liposomes was 100 nm ± 10 nm as determined using quasi-electric light scattering (QELS) (ZetaPals, Brookhaven). For studies assessing the influence of liposome size, smaller liposomes were prepared by extruding through two stacked 80 nm polycarbonate filters and larger liposomes were prepared by extruding through two stacked 200 nm polycarbonate filters. Liposomal lipid concentration was determined by measuring 3 H-CHE using liquid scintillation counting (Packard 1900TR Liquid Scintillation Analyzer). Liposome surface charge analysis was performed using a Malvern 3000 HS-Zetasizer (Malvern instruments Ltd., Malvern, UK).
CBDCA Solubility and Stability
Supersaturated solutions of CBDCA were prepared in the presence and absence of ethanol. CBDCA was added to SH buffer (50 mg CBDCA per mL buffer) and then mixed continuously at 20, 40, 60 or 70°C for 1 h. Samples were then allowed to cool to room temperature and insoluble CBDCA was pelleted via low speed centrifugation (Beckman Coulter Allegra X-15R). The concentration of CBDCA in the supernatant was estimated by measuring platinum (Pt) using atomic absorption spectroscopy (AAS) (AAnalyst 600, Perkin Elmer). In separate studies, a 40 mg/mL CBDCA solution prepared at 70°C was cooled to 60, 40 and 20°C and incubated for 1 h to determine the temperature at which solubilized CBDCA precipitated from solution. Since the assay for CBDCA only measured Pt concentration, we confirmed whether heating and addition of ethanol to CBDCA affected the cytotoxic activity of CBDCA against the U-251 MG glioblastoma cell line. Cells were seeded in 384-well plates and treated 24 h later. After a 72 h drug exposure, the cells were stained with Hoechst 33,342 and ethidium homodimer I for total and dead cell counts, respectively. Cells were subsequently imaged using INCELL Analyzer 2200 (GE Healthcare Life Sciences) and cell viability was measured based on viable nuclei count using the Developer Toolbox 1.9 software (GE Healthcare).
Liposome Stability in the Presence of Ethanol
Pre-formed DSPC/Chol (55:45) liposomes were prepared such that following extrusion, the mean liposome size was approximately 80, 100 and 200 nm. Liposomes were then incubated at three different temperatures (25, 40 
Passive Equilibration
CBDCA (40 mg/mL) was added to the specified 100 nm pre-formed liposomes. Liposomes were incubated at the corresponding temperatures in the presence of the indicated amount of ethanol for 1 h. Prior to removing unencapsulated CBDCA, the samples were equilibrated to RT and then liposome-associated CBDCA was separated from free drug by passing samples (100 μL) through 1 mL Sephadex G-50 spin columns equilibrated with SH buffer. Ethanol was exchanged out of the liposome solution by size-exclusion chromatography but we believe other methods such as dialysis could be used to remove ethanol. To confirm the complete removal of ethanol, ALCO screen alcohol test strips, which can measure N0.02% alcohol, were utilized. Liposome-associated CBDCA was measured using AAS and lipid concentration was determined by quantification of 3 H-CHE using liquid scintillation counting (Packard 1900TR Liquid Scintillation Analyzer, where). CBDCA association was measured as a function of time (over 1 h) and temperature (70°C, 40°C and RT).
For comparison, CBDCA was also encapsulated in liposomes using passive loading methods. Lipid films were prepared as described above and then rehydrated at 70°C with a solution of 40 mg/mL CBDCA in SH buffer. The hydrated multi-lamellar liposomes were then extruded 10 times through two stacked 0.10 μm polycarbonate filters. The resultant liposomes were sized by QELS methods and the amount of liposome associated CBDCA was determined as described above. After removal of unencapsulated CBDCA, the sample was analyzed for liposomal lipid and CBDCA as described above.
CBDCA Release and Liposome Stability
CBDCA containing liposomes were incubated in 50% FBS in SH buffer at 37°C with constant mixing. At selected time points, 100 μL was passed through a mini-Sephadex G50 spin column equilibrated with SH buffer. The columns were centrifuged at 680 x g for 3 min at 25°C. Liposome-associated CBDCA was measured in the filtrate by AAS. Similarly, 14-day liposome stability was assessed by storing the sample in SH buffer at 4°C and assaying for encapsulated CBDCA (as described above) on days 1, 7 and 14.
Cryo-EM methods
Cryo-electron microscopy (CEM) analysis was performed using a Zeiss Libra 120 transmission electron microscope at the University of Uppsala, Sweden. Liposomes were prepared as described above and loaded with CBDCA in SH buffer at pH 7.4. In a temperature and humidity controlled chamber, 1-2 μL of the sample was placed on a copper grid coated with a holey cellulose acetate butyrate polymer. Excess liquid was blotted away carefully using filter paper and then quickly vitrified by plunging into liquid ethane. The copper grid was then transferred to liquid nitrogen to maintain a temperature below 108 K. Images were taken in a zero-loss bright-field mode and an accelerating voltage of 80 kV.
Tumor Efficacy Models
The in vivo efficacy of DSPC/DSPG/Chol (70:20:10) liposomes was tested in two subcutaneous (sc) tumor models. Female Rag-2 M mice (n = 4-6) were inoculated sc with H1975 ( 
Statistical analysis
All data are plotted using the Prism 6.0 software (GraphPad) as mean ± SEM or mean ± SD as indicated in the figure legends. Comparisons between two groups were completed using the Student's t-test. Statistical analyses on studies with more than two groups were performed using one-way ANOVA followed by Tukey adjustments to correct for multiple comparisons. A p-value b 0.05 was considered statistically significant.
Results
CBDCA Solubility and Stability
The passive equilibration method described here relies on the ability to make concentrated solutions of the drug of interest. The ready-to-inject CBDCA product from Hospira comes as a 10 mg/mL solution; however, it was anticipated that higher concentrations could be achieved by dissolving the drug in solution at higher temperatures. The solubility of CBDCA at different temperatures was determined and the results have been summarized in Fig. 1 . CBDCA was added to SH buffer such that if all the added drug was solubilized the final concentration would be 50 mg/mL. When incubating this mixture at 70°C for 1 h, the maximum soluble concentration achieved was 46 mg/mL (Fig. 1A, black bars) . When incubated at 40°C, the maximum achievable concentration was just above 25 mg/mL. To assess the stability of the CBDCA solutions prepared at 70°C, the samples were incubated for another hour at 20, 40, 60 or 70°C and the results (Fig. 1B) confirm that once solubilized at the higher temperature, the drug did not precipitate after cooling for at least 1 h. In order to assess whether ethanol could act as a permeability enhancer, the CBDCA solubility studies were repeated in the presence of 30% (v/v) ethanol (black bars, Fig. 1A and B) . The results suggest that the maximum achievable CBDCA concentration was slightly (albeit not significantly) lower in the presence of ethanol. At 70°C, the CBDCA was 42 mg/mL in the presence of ethanol as compared to 46 mg/mL in the absence of ethanol.
There was a concern that heating CBDCA at 70°C in the presence of ethanol could inactivate the drug. Therefore, the cytotoxic activity of CBDCA against U251 glioblastoma cells was determined for the clinical CBDCA product and this was compared to CBDCA solutions prepared in SH buffer and incubated at 70°C for 1 h and 30% ethanol (v/v). The results (Fig. 1C) indicate that the IC 50 of CBDCA was unchanged (~8 μM) between the 2 solutions. When considering this data it can be ) or SH buffer with 30% ethanol ( ) at 20, 40, 60 or 70°C with mixing for 1 h. Then, samples were cooled to room temperature and after centrifugation of insoluble carboplatin, platinum concentrations were measured by AAS. (B) Carboplatin was prepared at 40 mg/mL and 70°C followed by incubation at lower temperatures without mixing for 1 h to allow for sedimentation of undissolved CBDCA and measure platinum concentrations in solution. Each data point represents mean ± SD (n = 3). (C) Cytotoxicity curves for CBDCA (ready to inject) (•) and CBDCA (40 mg/mL) in SH buffer with 30% ethanol heated for 1 h at 70°C (■) obtained with INCELL Analyzer in U-251 glioblastoma cell lines. When using the latter solution, the dilutions made for the cytoxicity studies insured that the final concentration of ethanol when added to the cells was b0.05%. Control studies (not shown) demonstrate that the viability of the cells was not affected in the presence of 0.05% ethanol. Values given are mean ± SD (n = 3).
suggested that solutions of CBDCA can be made at concentrations of 40 mg/mL at 70°C in the presence and absence of ethanol without affecting its cytotoxic effects.
Liposome Stability in Ethanol
The stability of liposomes as assessed by changes in liposome size in the presence of increasing ethanol concentrations was determined at different temperatures and the results summarized in Fig. 2 . Liposomes with mean diameters of 218 nm (column A), 104 nm (column B), and 84 nm (column C) were mixed with ethanol and incubated for 1 h at 70°C (Row I), 40°C (Row II) or 25°C (Row III). Liposome size was reassessed after the samples were returned to room temperature. The smaller liposomes (column C) were more stable in the presence of ethanol than the 100 and 200 nm preparations. At 70°C, the 84 nm liposomes in the presence of 40% ethanol had an increase in size of b 3-fold while the 100 nm liposomes increased in size by N10-fold. Further, the stability of the liposomes was greater when the preparations were incubated at lower temperatures. For example, 100 nm liposomes showed little change in size when incubated at 25°C in the presence of 40% ethanol while at 40°C and 70°C there was a N 2-fold and N10-fold increase in size, respectively. DSPC/Chol liposomes, regardless of size, appeared to be stable at all temperatures when incubated in the presence of ≤30% (v/v) ethanol.
The stability of 100 nm DSPC/DSPG/Chol (70:20:10 mol ratio) in the presence of ethanol at 70°C was compared to 100 nm DSPC/Chol (55:45 mol ratio) and the results are summarized in Fig. 3 . DSPC/ DSPG/Chol liposomes were only able to tolerate incubations with ethanol to maximum concentration of ≤25% (v/v) (Fig. 3A, filled squares) . These low-cholesterol liposomes gelled when the ethanol concentration was increased to 30% (v/v). The highest concentration of ethanol which showed stability at 1 h was selected for an assessment of stability (size) over a 2-h time course (Fig. 3B) . The DSPC/Chol liposomes showed a small, but reproducible, increase in size when ethanol (30%) was first added. Further increases in liposome size were not noted unless the sample was incubated for longer than 90 mins. This is in contrast to the 100 nm DPSC/DSPG/Chol liposomes which showed no initial change in size when mixed with 25% (v/v) ethanol even after 2 h incubation.
Encapsulation of CBDCA by Passive Equilibration
CBDCA was used to exemplify the passive equilibration method for DSPC/Chol and DSPC/DSPG/Chol liposomes of 100 nm as model systems (Fig. 4A) . CBDCA (40 mg/mL) was added to the liposomes in the presence of different concentrations of ethanol and incubated at 70°C for 1 h (Fig. 4B) . The amount of added CBDCA that associated with the liposomes over 1 h was determined (see Methods). The results for the DSPC/Chol liposomes indicate that after 1 h at 70°C in the absence of ethanol, the maximum amount of loading, reflected by the measured platinum (Pt)-to-lipid (L) ratio, was b 0.05 (mol ratio). When the ethanol concentration was increased to 30% (v/v), the Pt/L ratio increased N 4-fold. The loading efficiency was even greater for the DSPC/DSPG/Chol formulation where the Pt/L ratio increased from b 0.03 in the absence of ethanol to N0.25 in the presence of ethanol.
CBDCA loading efficiency was time, temperature, and ethanol concentration dependent as illustrated by the data summarized in Fig. 4C (DSPC/Chol liposomes) and 4D (DSPC/DSPG/Chol liposomes). Importantly, equilibration across the DSPC/Chol lipid bilayer was only achieved when the incubation temperature was 70°C. Since a 40 mg/mL CBDCA solution is 108 mM at equilibrium the maximum Pt/ L ratio achievable would be 0.24, assuming that the 100 nm liposomes had an estimated trapped volume of 2.2 μL per μmole lipid [9] and the liposomal lipid concentration was 40 mM. The addition of ethanol even with heating up to 40°C was not sufficient to allow CBDCA Fig. 2 . DSPC:Chol (55:45) liposomes were incubated with ethanol concentrations of 0-40% v/v. Liposomes were prepared through extrusion at varying sizes (Column A -200 nm, column B − 100 nm and column C -80 nm) and incubated at different temperatures (Row I -70°C, row II -40°C and row III -25°C) for 1 h. Samples were cooled prior to sizing the liposomes with the ZetaPals particle sizer as described in the Methods. Liposomes were extruded at 65°C. All experiments were performed at a final concentration of 50 mM lipid. Mean particle size for 3 independent experiments ± SD. equilibration, indicating that neither heating nor ethanol (30% v/v) alone is sufficient for equilibration to occur. Liposomes were prepared in SH buffer or PBS and were loaded with CBDCA using passive equilibration for 1 h at 70°C. The use of another buffer system did not result in any changes to drug loading or liposome size, as shown in Fig. 4E and F. Notably, when CBDCA is encapsulated in the two selected liposomal compositions using passive encapsulation methods (where drug is added during lipid rehydration prior to extrusion at the same concentration), the amount of CBDCA associated with the liposomes was significantly (~2-fold) less (Fig. 5) .
CBDCA release from DSPC/Chol and DSPC/DSPG/Chol liposomes was assessed at 37°C in a buffer containing 50% FBS and the results are summarized in Fig. 6 . Both formulations appeared relatively stable over a 24 h incubation (Fig. 6A) . The DSPC/DSPG/Chol formulation released CBDCA at a faster rate than the DSPC/Chol formulation over the first 6 h. Liposomes prepared using passive equilibrations were also stable when stored at 4°C; there was no significant CBDCA release from the liposomes over the 14 day time-course ( Fig. 6B) . Fig. 6C provides representative cryo-TEM images of the CBDCA loaded and unloaded liposomes. Visually, the liposomes appeared to be the same before and after loading. Even though the liposomes were loaded using a supersaturated solution of CBDCA, there was no evidence of electron-dense precipitates inside the CBDCA-loaded liposomes.
In vivo evaluations of the CBDCA formulations
Preliminary studies assessing the pharmacokinetic behavior and efficacy of the CBDCA formulations prepared by passive equilibration has been summarized in Fig. 7 . When administered as single agents at equivalent doses (10 mg/kg given i.v), the liposomal formulations enhanced the circulation longevity of CBDCA when compared to the clinical product (Fig. 7A) . The DSPC/Chol liposomal formulation did exhibit a 1.7-fold higher AUC of 1014.0 μg·hr/mL when compared to the DSPC/DSPG/Chol formulation AUC of 583.96 μg·hr/mL. Both formulations showed a N 30,000 fold increase in AUC in comparison to free CBDCA (0.016 μg·hr/mL) in the plasma compartment. These studies suggest that the liposomal lipid elimination was comparable for the two selected formulations (Fig. 7B) , with approximately 14.4 and 5.0% of the injected lipid dose remaining in the plasma compartment at 24 h for the DSPC/Chol and DSPC/DSPG/Chol formulations respectively. By evaluating the calculated Pt/L ratios using the data presented in Fig.  7A and B, it can be suggested that the DSPC/DSPG/Chol liposomes released CBDCA more rapidly than the DSPC/Chol liposomes (Fig. 7C) . Specifically, after 24 h, the Pt/L ratio for the DSPC/DSPG/Chol formulation was b0.02, indicating N90% loss of associated CBDCA. In contrast, the DSPC/Chol liposomes exhibited b50% loss of associated drug over the same time course. Dose range finding studies were completed prior to initiating these studies and it was determined that the maximum tolerated dose (MTD) (which resulted in b10% body weight loss when administered using a Q4D × 3 schedule) was 20, 5 and 10 mg CBDCA/kg for the clinical product (Hospira), DSPC/Chol liposomes and DSPC/DSPG/Chol, respectively.
Two sc tumor models were used to assess the efficacy of the DSPC/ DSPG/Chol formulation. We focused on this formulation because it was better tolerated than the DSPC/Chol liposomal formulation and because the PK studies suggested that CBDCA was released from the liposomes in the plasma compartment. Tumor growth was determined as a function of time following initiation of treatment and the study was halted when control animals reached humane endpoints on days 21 and 43 for H1975 (Fig. 7D ) and U-251 (Fig.7E ) sc models respectively (see Methods). For these studies we compared the activity of free drug and liposomal formulations at the MTD. For the H1975 model, the results suggest that the DSPC/DSPG/Chol formulation of CBDCA achieved the largest reduction in tumor size as determined on day 21. The DSPC/DSPG/Chol liposomal formulation was the only treatment group that resulted in a statistically significant reduction in tumor burden when compared to the vehicle treated control group. Even at twice the CBDCA dose of the liposomal formulation, treatment with free CBDCA did not induce a significant decrease in tumor volumes in the H1975 model. For the U-251 tumor model, a statistically significant reduction in tumor burden was found for the liposomal and unencapsulated CBDCA MTD-treated groups; however, the activity of the liposomal formulation was comparable to that of the free drug.
Passive equilibration of other lipid compositions
The passive equilibration method is expandable to other lipid compositions easily through 4 steps. (i) prepare liposomes of the preferred composition, (ii) determine liposome/ethanol stability (incubate with varying concentrations of ethanol at a temperature above the transition temperature), (iii) passive equilibration by incubating lipsomes, CBDCA at 40 mg/mL and ethanol (concentration chosen from step 2) for 1 h at the corresponding temperature above the transition temperature and (iv) remove unencapsulated CBDCA (allow liposomes to cool and remove drug through size-exclusion chromatography). This process was shown for 2 additional lipid compositions DSPC/Chol/DSPE-PEG 2000 (65:30:5) and DSPC/DSPE-PEG 2000 (95:5) in Fig. 8 . Both preparations were stable at 30% ethanol for 1 h at 70°C but incubation with higher ethanol concentration resulted in size increases (Fig. 8A/B) . Both preparations were loaded with CBDCA using passive equilibration and compared to our original formulations (DSPC/Chol and DSPC/DSPG/Chol) in Fig. 8C (Fig. 8D) , it was found that loading doubled to a Pt to lipid ratio of 0.11 by 4 h. There was a small increase in size (~10%) but no change in liposome surface charge when CBDCA was equilibrated over 4 h. The liposome size and surface charge were examined before and after loading for all formulations . Both liposome preparations were extruded at 65°C. All experiments were performed at a final concentration of 50 mM lipid. Size was measured using a ZetaPals particle sizer. Mean particle size for 3 independent experiments ± SD. (Table 2 ). DSPC/DSPE-PEG 2000 (95:5) formulation did show a small size increase but all formulations showed no changes in surface charge after loading.
Discussion
Preparing drug loaded liposomes using passive equilibration methods is simple and suitable for drug candidates that are extremely water soluble. Furthermore, when considering highly toxic drug candidates, passive equilibration methods avoid some of the significant safety concerns that arise when manufacturing liposomes in the presence of the drug. Whether extrusion or microfluidic mixing methods are being used to prepare the liposomes, manufacturing requires multiple steps and containment issues increase with each manufacturing step. Here we describe the passive equilibration method which uses permeability enhancers to facilitate encapsulation of candidate drugs after Table 1 showing the size of DSPC/Chol (55:45) liposomes prepared in SH or PBS buffers, before and after loading of CBDCA using passive equilibration at 70°C with 30% ethanol. Platinum was measured via AAS and lipid was measured using scintillation counting. Size was measured using a ZetaPals particle sizer. Both liposome preparations were extruded at 65°C. All experiments were performed at a final concentration of 20 mM lipid. the liposomes have been manufactured and achieves higher drug loading efficiencies. The factors that influence drug encapsulation by passive equilibration methods are discussed below.
The main difference between passive encapsulation and passive equilibration is that for passive equilibration, loading is completed after the liposomes have been prepared. Both processes yield liposomes of the selected lipid composition containing the drug of interest and although no formal side-by-side comparison has been performed, we do not believe that liposomal formulations prepared by passive equilibration methods will behave differently from liposomes prepared using passive encapsulation methods. Ethanol removal was confirmed using ALCO test strips which shows that b 0.02% of ethanol is present in the sample, yielding liposomes of identical composition. It is important to note that liposomes prepared using passive equilibration methods were shown to have better trapping efficiency and thus higher drug to lipid ratios. Passive encapsulation yields lower trapping efficiencies due to an effect referred to as non-equilibrium solute distribution. This has been described by Mayer et al. [19] , and essentially relates to the fact that when hydrating dried lipid films that water permeates across the forming lipid bilayers faster than the solute does. For this reason the trapped water volume is often much greater than the volume predicted on the basis of entrapped solute. This was first reported by Gruner et al. [36] and the fact that the passive equilibration method described here avoids this problem highlight another merit for use of this method. It is known that drug to lipid ratio can affect the activity of the formulation for some drugs, but this has never been noted for CBDCA formulations [7] . In order to minimize dilution of the added drug, it is important that the drug is added in solid form and dissolved in a solution containing the liposomes. If it is possible to create supersaturated ) or passive equilibration ( ). Pt to Lipid ratio is given for each final product as measured using AAS and scintillation counting. Both liposome preparations were extruded at 65°C. All experiments were performed at a final concentration of 20 mM lipid. Data is given as mean ± SD for at least 3 independent loading experiments. * indicates significantly different comparisons p b 0.05. The formulations were allowed to equilibrate to 25°C post loading followed by size-exclusion chromatography to remove unloaded CBDCA. Samples were cooled prior to sizing the liposomes with the ZetaPals particle sizer as described in the Methods. Platinum was measured via AAS and lipid was measured using scintillation counting. Liposomes were extruded at 65°C. All experiments were performed at a final concentration of 20 mM lipid.
solutions of the drug of interest, then the final product will exhibit the highest possible drug-to-lipid ratio for liposomes of a specific size range. In the example provided here, concentrations N 40 mg/mL CBDCA were achievable by heating to 70°C. The maximum achievable concentration of CBDCA was not affected by the addition of ethanol. Additionally, the cytotoxic activity of CBDCA was unaffected by exposure to 70°C and/or ethanol. The use of ethanol to prepare and manufacture liposomes has been established previously [25, 37] . Further, high ethanol concentrations (20-45%) have been used in the creation of ethosomes, a liposomal formulation which uses ethanol as a component to increase permeability in subcutaneous tissues for transdermal delivery [38] [39] [40] . The studies described here identify the amount of ethanol and temperature required to enhance the permeability of the liposomal lipid bilayer to CBDCA without causing significant change in liposome size. This enhanced permeability has been exploited in order to load CBDCA into pre-formed liposomes. It is anticipated that the effects of ethanol will be dependent on liposome lipid concentration as well. Liposomes were loaded using passive equilibration in the presence of SH and PBS buffers at pH 7.4 without any significant changes in particle size. The effects of lipid composition were illustrated here by differences between DSPC/Chol and DSPG/DSPC/Chol liposomes. While the transition temperature (T c ) of DSPC lipid is 55°C, the use of Chol increases the T c as noted by Redondo-Morata et al. [41] This could explain why the DSPC/ Chol formulation with 45 mol percent Chol was slightly more stable than the low cholesterol formulation (10 mol%). It should be noted that as the intended application of potential lipid compositions may differ from those described here, optimization of ethanol concentrations and temperature would be needed for each specific formulation and drug of interest. At the lipid concentrations used, smaller liposomes (80 nm) appeared to be more stable, albeit not significantly, than the large liposomes (200 nm). The destabilizing effects of ethanol, as judged by increases in liposome size, were enhanced at higher temperatures compared to lower temperatures. This can be explained by studies done by Tran et al. [42] wherein the T c of DSPC lipid bilayers of multilamellar vesicles (MLVs) were observed in the presence and absence of ethanol using differential scanning calorimetry (DSC). The results showed a decrease in phase transition temperature which explains why ethanol may behave as a permeability enhancer.
The approach described here allows CBDCA to equilibrate across the liposomal lipid bilayer when the appropriate concentration of ethanol is combined with heating. Without heating, there was no significant CBDCA encapsulation even at the maximum ethanol concentrations analyzed. Others have attempted to employ passive equilibration to load CBDCA into cholesterol-free formulations without adding ethanol and instead relying solely on the transition temperature of the lipid used to prepare the liposome [43, 44] . The current study demonstrates that while this approach may work, it is not suitable for cholesterol-containing systems. Regarding the differences in CBDCA permeability between the different formulations it is important to note that based on previous literature, it was not possible to predict which formulation would retain drug better or why. In general, the effect of lipid composition on drug release rates must be determined empirically. It is reasonably well understood that the permeability of an entrapped agent is dependent on the entrapped drug and the liposomal lipid composition. At this point, it is difficult to predict release attributes for a drug based solely on liposomal lipid composition. As an example, previous work from our laboratory demonstrated that the anthracycline idarubicin is retained better in vivo in cholesterol free liposomes [45] ; however, other anthracyclines, such as doxorubicin, are less retained in these liposomes when compared to cholesterol containing formulations such as DSPC/Chol.
The two formulations prepared using passive equilibration entrapped 2-fold the amount of CBDCA than the passively encapsulated systems. This higher platinum to lipid ratios were not possible prior to the development and application of this method and thus the products might differ in vivo as twice the lipid dose of the passively encapsulated formulation would be required to achieve the same amount of CBDCA as the passive equilibrated formulation.
This manuscript describes an improved method for preparing liposomal CBDCA formulations and we are pursuing the development of such preparations as components for combination products to treat aggressive forms of cancer. Preliminary data provided here indicates that the formulations prepared using passive equilibration methods are suitable for i.v. use. Further, the formulations engender significant decreases in plasma CBDCA elimination rates. Note that the drug release profile in vitro differs greatly from that in vivo (compare Figs. 6 & 7) . This is not surprising and has been noted elsewhere [46] . We argue that this is true for most liposomal formulations as the "sink" into which the released drug enters is limited in vitro whereas in vivo there is an essentially limitless sink due to drug distribution throughout the body. In vitro studies could be designed to address this, in part, by evaluating release rates at decreasing concentrations of liposomal lipid. This can become a practical challenge if the assay sensitivity of the encapsulated drug is poor. The DSPC/DSPG/Chol formulation was selected over the DSPC/Chol formulation for animal studies due to what we believe is more favorable drug release kinetics as well as the DSPC/Chol formulations exhibited additional toxicity when given at equivalent doses on the same schedule. This increased toxicity is not uncommon; it has been observed that some liposomal formulations are more toxic than the free drug. This has been best illustrated for formulations of doxorubicin and mitoxantrone [47, 48] . For example, the DSPC/Chol (55:45) doxorubicin formulation is 3-fold less toxic than free drug whereas the DMPC/Chol (55:45) doxorubicin formulation is 3-fold more toxic than the free drug. This observation is likely related to the unique pharmacokinetic/ Table 2 Liposome characterization before and after loading with CBDCA through passive equilibration. toxicity relationship of doxorubicin wherein the toxicity is related to high plasma concentrations of free doxorubicin which is seen with the "leakier" DMPC/Chol liposome but not the DSPC/Chol formulation. It is important to note in this context that DMPC/Chol liposomes are eliminated at comparable rates to DSPC/Chol liposomes. Our data suggests that the CBDCA formulations are more toxic than free drug which is likely a result of the enhanced in vivo exposure of the drug. It is likely that CBDCA which is known to have a rapid renal elimination becomes more toxic when it is circulated for a longer period of time in the liposome [49] . Both formulations have shown a longer circulation lifetime than the free drug at equivalent (10 mg/kg) doses. Despite DSPC/Chol releasing CBDCA from liposomes into the plasma compartment slowly this formulation can exert toxicities following the distribution and metabolism of the liposomes and subsequent release of associated CBDCA. In contrast, the DSPC/DSPG/Chol liposomes release CBDCA more rapidly and this likely allows for enhanced renal elimination of CBDCA and an associated reduction in toxicity. The current formulations are not suitable for further development based on the data provided in Fig. 7 . However the method used to prepare these formulations will allow us to rapidly screen other compositions that may be more suitable for further development. Liposomal preparations of cisplatin prepared using passive encapsulation methods in which drug contents were retained well in vivo showed little efficacy in a P388 murine lymphocytic leukemia tumor model [50] . This is similar to the case seen here with DSPC/Chol liposomes loaded with CBDCA and would suggest that this formulation is not worth further in vivo assessments. The DSPC/DSPG/Chol formulation resulted in statistically significant decrease in tumor burden in both H1975 and U251 models of lung and glioblastoma cancers when compared to vehicle controls. Unfortunately, the liposomal CBDCA formulations were unable to produce stable disease (reflected as no increase in tumor progression following treatment initiation), a partial (50% reduction in measurable disease) or a complete response (elimination of measurable disease) in disease and thus the utility of these formulations used as single agents is considered limited. It should be noted that U251 is platinum sensitive, whereas H1975 was found to be platinum insensitive [51] . We do argue, however, that selected formulations could be exploited in the context of combinatorial therapy. It is known that CBDCA is active in the treatment of patients with glioblastoma and it is able to cross the blood brain barrier (BBB) [52] . Future studies will evaluate the therapeutic activity of liposomal CBDCA formulations given as part of a combination treatment for glioblastoma [53, 54] as well as provide a more extensive biodistribution analysis. Since CBDCA is also commonly used as first line treatment for other solid tumors such as those in head and neck, lung, and ovarian cancers [55] , additional optimization will be required to design a specific CBDCA formulation to be used in combination with existing cytotoxic drugs and/or targeted agents for each disease indication.
The passive equilibration methodology can be applied to other lipid compositions to encapsulate drugs. This process does need some optimization, an ethanol concentration and temperature need to be determined. These conditions can be done without the drug of interest and determine the conditions required equilibration. We have successfully shown the passive equilibration of four different lipid compositions with varying concentrations of Chol and with and without PEG. The DSPC/Chol/DSPE-PEG 2000 (65:35:5) and DSPC/DSPE-PEG 2000 (95:5) were both found to be stable at 30% ethanol for at least 1 h. Interestingly, when this was done in the presence of CBDCA and allowed to passively equilibrate the DSPC/ DSPE-PEG 2000 (95:5) formulation only reaches a Pt to lipid ratio of~0.05 after 1 h. This is in contrast to DSPC/Chol/ DSPE-PEG 2000 (65:35:5) which reaches~0.2. This would suggest that Chol allows for a quicker loading process, to confirm this DSPC/DSPE-PEG 2000 (95:5) liposomes were incubated with ethanol for 4 h (Supplementary) and showed no significant increase in size or PDI. They were then incubated with ethanol and CBDCA, after 4 h a final Pt to lipid ratio of 0.1 was obtained, indicating that passive equilibration occurs more slowly in Chol free formulations. Although, passive equilibration can be done in this Chol free formulation with ethanol, other solvents could be used to potentially enhance the equilibration process.
Conclusion
For many candidate drugs where remote liposomal loading methods cannot be used, passive equilibration methods provide a suitable alternative. The success of this method relies on the use of permeability enhancers that do not cause changes in liposome structure and where the permeability can be controlled through use of temperature or rapid removal of the permeability enhancer used. Here, we demonstrate that in the presence of 30% ethanol, CBDCA readily equilibrates across the liposomal lipid bilayer of four different formulations (DSPC/Chol, DSPC/ DSPG/Chol, DSPC/Chol/DSPE-PEG 2000 and DSPC/DSPE-PEG 2000 ) when incubated at 70°C, but no equilibration is observed at room temperature. Further, in the absence of ethanol, limited CBDCA diffuses into the liposome interior even when incubated at 70°C. The approach described here is expected to be extendable to other permeability enhancers including, for example, class 3 solvents deemed by the FDA to be less toxic and negative in genotoxicity studies.
